In an interview with CURE, Dr. Lakshmi Nayak explains how an FDA label update expands Yescarta access for relapsed or refractory primary CNS lymphoma. In an interview with CURE, Dr. Lakshmi Nayak, a ...

The FDA on Thursday approved label changes for six hormone replacement therapies (HRTs) that remove boxed warnings for cardiovascular disease, breast cancer, and probable dementia. For more than two ...

Timi is a news and deals writer who's been reporting on technology for over a decade. He loves breaking down complex subjects into easy-to-read pieces that keep you informed. But his recent passion ...

Immigration officials are testifying before the House Homeland Security Committee on Tuesday for the first time since two U.S. citizens were killed in the recent immigration crackdown in Minneapolis.

Dana-Farber Cancer Institute-led research helped drive an FDA label update for axicabtagene ciloleucel (Yescarta) that removes a prior exclusion for patients with primary central nervous system ...

The FDA has updated the safety labeling for axicabtagene ciloleucel (Yescarta, Kite Oncology) ­— a CAR T-cell therapy — extending its indication to include patients with relapsed or refractory primary ...

(RTTNews) - Kite, a Gilead Company (GILD), announced the FDA approved an update to the Yescarta prescribing information removing the previous Limitations of Use in patients with relapsed or refractory ...

Kite, a Gilead Company, today announced the U.S. Food and Drug Administration approved an update to the Yescarta ® prescribing information removing the previous Limitations of Use in patients with ...

The FDA has updated the product labeling of capecitabine (Xeloda, Genentech) and fluorouracil to reflect the risks of acute toxicity and potentially fatal adverse reactions in patients with ...

New guidelines clarify labeling, allowing foods dyed with natural sources while keeping synthetic dyes off the label. Winter storm warning for 11 states as up to 4 feet of snow forecast Person shoots ...

Amgen Inc (NASDAQ: AMGN) reported better-than-expected fourth-quarter revenues and earnings, while witnessing "strength across key drivers (Repatha, Uplizna), even before the full impact of recent ...